骨质疏松症是一种全身性骨代谢疾病，其病因非常复杂，骨重建失衡是其中的一个关键因素。受体激活核因子κB配体/受体激活核因子κB/骨保护因子(RANKL/RANK/OPG)通路在骨重建及骨代谢过程中具有重要作用，是治疗骨质疏松症的重要靶点。但目前尚无针对该靶点的小分子药物，且该信号通路的研究仍有待深入。荧光团激活蛋白（FAP, Fluorogen activating proteins）成像系统具有荧光强度高、背景干扰小、免清洗等优势，可用于信号通路的标记。本课题拟以成骨-破骨细胞体系中具有重要介导作用的RANKL为媒介，采用FAP标记RANKL的荧光成像技术，研究先导化合物E48406在成骨细胞-破骨细胞共培养体系中的作用机制，实现成骨破骨细胞相互作用的实时、可视化追踪，为阐明化合物的作用机制研究提供了有利平台，为开发新型抗骨质疏松药物提供了新的筛选平台。

Osteoporosis is a systemic bone metabolic disease, the cause of which is complex, and bone remodeling imbalance is one of the key factors. The receptor activated nuclear factor κB ligand/ receptor activated nuclear factor κB/ Osteoprotegerin (RANKL/RANK/OPG) pathway plays a vital role in bone remodeling and metabolism, which has been an important target for osteoporosis treatment. However, there is still no small-molecule drugs targeted on RANKL/RANK/OPG, and the pathway still needs in-depth study. Fluorogen activating proteins (FAP) imaging system has the advantages of high fluorescence intensity, low background interference, no-washing and can be used to label signal pathways. This subject intends to label RANKL, which has an important mediating role in the osteoblast-osteoclast system, using FAP fluorescence imaging technology to study the mechanism of lead compound E48406 in the osteoblast-osteoclast co-culture system. This subject will achieve real-time, visual tracking of the interaction of osteoblasts and osteoclasts and provide an advantageous platform for elucidating the mechanism of the compound and a new screening platform for the developing novel anti-osteoporosis drugs.